Stockscreener 앱 받기
4.88
3.56%
-0.18
시장 영업 전:
4.75
-0.13
-2.66%
전일 마감가:
$5.06
열려 있는:
$5.12
하루 거래량:
504.48K
Relative Volume:
0.54
시가총액:
$400.39M
수익:
$531.00K
순이익/손실:
$-99.96M
주가수익비율:
-2.2264
EPS:
-2.1919
순현금흐름:
$-98.96M
1주 성능:
+0.83%
1개월 성능:
+4.72%
6개월 성능:
-22.42%
1년 성능:
+2.09%
1일 변동 폭
$4.84
$5.204
1주일 범위
$4.82
$5.405
52주 변동 폭
$3.99
$10.99
Lexeo Therapeutics Inc Stock (LXEO) Company Profile
명칭
Lexeo Therapeutics Inc
전화
(212) 547-9879
주소
345 PARK AVENUE SOUTH, NEW YORK
Compare LXEO vs VRTX, REGN, ARGX, MRNA, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
LXEO
Lexeo Therapeutics Inc
|
4.88 | 415.15M | 531.00K | -99.96M | -98.96M | -2.1919 |
VRTX
Vertex Pharmaceuticals Inc
|
548.05 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
834.04 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,039.78 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.13 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
209.46 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Lexeo Therapeutics Inc Stock (LXEO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-18 | 개시 | Raymond James | Strong Buy |
| 2025-11-20 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-10-15 | 개시 | Guggenheim | Buy |
| 2025-07-31 | 개시 | Oppenheimer | Outperform |
| 2024-06-13 | 개시 | Robert W. Baird | Outperform |
| 2024-06-06 | 개시 | H.C. Wainwright | Buy |
| 2023-11-28 | 개시 | Chardan Capital Markets | Buy |
| 2023-11-28 | 개시 | JP Morgan | Overweight |
| 2023-11-28 | 개시 | Leerink Partners | Outperform |
| 2023-11-28 | 개시 | RBC Capital Mkts | Outperform |
| 2023-11-28 | 개시 | Stifel | Buy |
모두보기
Lexeo Therapeutics Inc 주식(LXEO)의 최신 뉴스
Balyasny Asset Management L.P. Expands Stake in Lexeo Therapeuti - GuruFocus
Lexeo Therapeutics (NASDAQ:LXEO) CEO Richard Nolan Townsend Sells 3,345 Shares - MarketBeat
Louis Edward Tamayo Sells 4,117 Shares of Lexeo Therapeutics (NASDAQ:LXEO) Stock - MarketBeat
Lexeo Therapeutics CFO Louis Edward Tamayo Sells 4,117 Shares to Settle RSU Tax Liabilities - Kalkine Media
Lexeo Therapeutics COO Jose Manuel Otero Sells Shares to Cover RSU Tax Liability - Kalkine Media
Lexeo Therapeutics CEO Richard Nolan Townsend Sells 3,345 Shares to Settle RSU Tax Liabilities - Kalkine Media
Lexeo Therapeutics (LXEO) CFO sells shares for RSU taxes - Stock Titan
Lexeo (NASDAQ: LXEO) CEO sale covers RSU tax bill, keeps 374K shares - Stock Titan
Lexeo Therapeutics (LXEO) COO sells 1,304 shares, retains 136K stake - Stock Titan
Lexeo (NASDAQ: LXEO) holder plans stock sale to cover tax bill - Stock Titan
Lexeo Therapeutics (LXEO) holder plans 1,304-share sale - Stock Titan
Lexeo Therapeutics (NASDAQ: LXEO) insider to sell 4,117 shares - Stock Titan
Lexeo Therapeutics (NASDAQ:LXEO) Stock Rating Lowered by Wall Street Zen - MarketBeat
Lexeo Therapeutics (LXEO): OrbiMed entities disclose combined 5% ownership stake - Stock Titan
Lexeo Therapeutics (LXEO): Paradigm BioCapital reports over 5% beneficial stake - Stock Titan
Balyasny Asset Management (LXEO) discloses 7.84M-share Lexeo Therapeutics stake capped at 9.99% - Stock Titan
Lexeo Therapeutics (LXEO): Affinity Asset Advisors reports 8.4% beneficial stake - Stock Titan
Hennion & Walsh Asset Management Inc. Invests $1.24 Million in Lexeo Therapeutics, Inc. $LXEO - MarketBeat
Lexeo Therapeutics Releases Q2 2026 Financial Results - AlphaStreet
Lexeo Therapeutics (NASDAQ:LXEO) Announces Earnings Results, Hits Estimates - marketbeat.com
META_TITLE_QUOTE - Yahoo Finance
Form 8K Lexeo Therapeutics Inc For: 12 August By Investing.com - Investing.com Nigeria
Lexeo Therapeutics advances gene therapy and gains RMAT status - TipRanks
LXEO: Gene therapies for rare cardiac diseases advance with strong data, pipeline, and financial runway - TradingView
Lexeo Therapeutics Reports Second Quarter 2026 Financial Results and Operational Highlights - The Manila Times
Lexeo Therapeutics Announces SUNRISE-FA 2 Trial Initiation for LX2006 and Receives FDA RMAT Designation for LX2020 - Quiver Quantitative
Lexeo Therapeutics, Inc. 2Q 2026: Net loss $25.9M, EPS $(0.30) — 10-Q Summary - TradingView
Lexeo Reports $25.9 Million Q2 Net Loss as SUNRISE-FA 2 Begins - Moomoo
Lexeo Therapeutics (LXEO) narrows loss and ends H1 2026 with $234M cash - Stock Titan
Dimensional Fund Advisors LP Increases Holdings in Lexeo Therapeutics, Inc. $LXEO - MarketBeat
Lexeo net loss narrows to $25.9 million in Q2 FY26; R&D expenses rise to $19 million - Bitget
Lexeo Therapeutics (LXEO) Short Interest & Short Float | Updated Aug 2026 - MarketBeat
Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Receives Average Rating of "Buy" from Brokerages - MarketBeat
Lexeo Therapeutics Inc (LXEO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
State Street (NYSE: STT) discloses 5.5% beneficial stake in Lexeo Therapeutics (LXEO) - Stock Titan
Lexeo's PKP2 cardiomyopathy gene therapy adds RMAT status - AllSci
Lexeo Therapeutics (LXEO) Projected to Release Earnings on Thursday - MarketBeat
Lexeo Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (Rmat) Designation For Lx2020 - TradingView
Lexeo Therapeutics Receives FDA Regenerative Medicine Advanced Therapy Designation For LX2020 For The Treatment Of PKP2 Arrhythmogenic Cardiomyopathy - marketscreener.com
Lexeo Therapeutics (LXEO) Advances 1.7% to $4.49, Holding Above Key SupportMid Cap Momentum - dars.gov.et
Lexeo wins FDA RMAT designation for LX2020 in PKP2 arrhythmogenic cardiomyopathy - Bitget
Lexeo wins FDA RMAT status for LX2020 - PharmaTimes
Lexeo Therapeutics, Inc. $LXEO Shares Sold by Janus Henderson Group PLC - MarketBeat
Lexeo Therapeutics (LXEO) Pulls Back 5% as Selling Pressure IntensifiesDaily Profile - dars.gov.et
Lexeo Therapeutics (NASDAQ:LXEO) Upgraded to Strong-Buy at Chardan Capital - MarketBeat
Lexeo Therapeutics Inc (LXEO) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Lexeo Therapeutics Inc (LXEO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Lexeo Therapeutics Inc (LXEO) Balance Sheet - TradingKey
Lexeo Therapeutics Inc (LXEO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Lexeo Therapeutics, Inc. Revenue Breakdown – NASDAQ:LXEO - TradingView
Lexeo Therapeutics Inc (LXEO) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Lexeo Therapeutics Inc (LXEO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.21%
1.07%
자본화:
|
볼륨(24시간):